We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Colorectal Cancer Relapses Predicted by Expression of Five Genes

By LabMedica International staff writers
Posted on 02 Oct 2014
Print article
Roche\'s LightCycler 480 Instrument for polymerase chain reactions
The LightCycler 480 Instrument for polymerase chain reactions (Photo courtesy of Roche Diagnostics)
The analysis of five differentially expressed genes could be used to classify colorectal tumors, predict the evolution of the patient and thus take appropriate clinical decisions to prevent relapses.

In order to accurately identify the characteristics of each tumor, good biomarkers are needed to predict the outcome of each patient and both malignant cells and normal accompanying cells which are a particular microenvironment, can be a source of these biomarkers.

Scientists the Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (ICO-IDIBELL; Catalonia, Spain) developed a tool based on the expression of five genes characteristic of the tumor microenvironment that allows classifying very accurately the prognosis of patients suffering from colorectal cancer (CRC) at an intermediate stage of the disease. Validation was performed in a metacohort of 317 and 142 CRC patients by means of real-time polymerase chain reaction (RT-PCR). To demonstrate that these five genes have prognostic value if the stroma is present in a given sample, they checked the signature in two independent datasets of LCM (Laser Capture Microscope) epithelial cell-enriched samples.

The selected genes were: chemokine (C-C motif) ligand 11 (CCL11), which is down regulated in carcinoma-associated fibroblasts (CAFs), versus paired normal colonic fibroblasts (NCF); and a protective gene; PDZ and LIM Domain 3 (PDLIM3), adhesion molecule with Ig-like domain 2 (AMIGO2), Solute Carrier Family 7 (Cationic Amino Acid Transporter, Y+ System), Member 2 (SLC7A2), and UL16 binding protein 2 (ULBP2), all overexpressed in CAFs versus paired NCF. RNA quantity was determined by NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies Inc.; Rockland, DE, USA). Quantitative PCR assays were performed with the LightCycler 480 (Roche Applied Science; Mannheim, Germany).

The authors concluded that the CAFs-derived five-gene classifier provided more accurate information about outcome than conventional clinicopathological criteria and it could be useful to take clinical decisions, especially in Stage II colorectal cancer. Additionally, the classifier put into relevance the CAF’s intratumoral heterogeneity and might contribute to find relevant targets for depleting adequate CAF’s subtypes.

David Garcia-Molleví, PhD, the principal investigator of the study said, “With the analysis of only five genes by routine techniques, we provide very precise information about the likelihood of relapse and the appropriateness of administering chemotherapy patients with stage II disease.” The study was published on August 30, 2014, in the journal Oncotarget.

Related Links:

Catalan Institute of Oncology 
NanoDrop Technologies Inc.
Roche Applied Science 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.